A multi-centre, open-label, uncontrolled, phase II study to investigate efficacy and safety of ONO-4538 in malignant pleural mesothelioma

Trial Profile

A multi-centre, open-label, uncontrolled, phase II study to investigate efficacy and safety of ONO-4538 in malignant pleural mesothelioma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 22 Dec 2017 Results presented in an Ono Pharmaceutical media release.
    • 22 Dec 2017 According to a company media release, based on the results of this trial, Ono Pharmaceutical Co., Ltd. has submitted a supplemental application of nivolumab (Opdivo Intravenous Infusion 20 mg and 100 mg) in Japan for the treatment of unresectable advanced or metastatic malignant pleural mesothelioma for a partial change in the approved items of the manufacturing and marketing approval.
    • 18 Oct 2017 Preliminary results (n=34) presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top